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Sir
Neurofibromatosis 2 (NF2) is a rare (1:40 000) autosomal domi-
nant disease that is caused by mutations of the NF2 tumour
suppressor gene. NF2 is characterized by benign nervous system
tumours such as vestibular schwannomas (VSs), intracranial
meningiomas and spinal tumours. Kondziolka et al (1998)
reported the outcomes of radiosurgery for unilateral sporadic VSs,
but NF2 patients were excluded and follow-up was limited. The
consequences of radiosurgery for histologically benign NF2
tumours merit study due to the mutagenic potential of ionizing
radiation. Somatic mutation could contribute to the transformation
or acceleration of existing tumours, and to the development of
secondary tumours, because NF2 patients have an inactivated
germ-line NF2 allele. Ionizing radiation is known to have such
effects in hereditary retinoblastoma (Wong et al, 1997). We
conducted this study because the prevalence of, and risk factors
for, malignant nervous system tumours in NF2 are unknown.
We surveyed genetics, otolaryngology and neurology/neuro-
surgery centres in North America and Europe with a total of 1348
NF2 patients. There were nine malignant nervous system tumours
in the estimated 1242 NF2 patients who did not have previous
radiosurgery. This prevalence of 725 per 105 (95% confidence
interval (CI) 253–1197 per 105) is significantly greater than the
population prevalence of 1.13 per 105 (95% CI 1.09–1.15 per 105)
(SEER Program Public-Use CD-ROM, 1998). There were five
malignant peripheral nerve sheath tumours (MPNSTs), two malig-
nant meningiomas, one malignant ependymoma and one
anaplastic astrocytoma (median age at tumour diagnosis, 14 years;
range 7–35 years). The population prevalences of these tumours
are MPNST, 0.00 per 105; malignant meningioma, 0.42 per 105;
malignant ependymoma, 0.05 per 105; and anaplastic astrocytoma,
0.66 per 105 (SEER Program Public-Use CD-ROM, 1998). Thus,
NF2 patients have a significantly increased prevalence of MPNST
(402 per 105; 95% CI 50–754 per 105).
After radiosurgery for benign tumours, five NF2 patients devel-
oped malignant tumours in high-dose areas (three MPNSTs, one
malignant meningioma and one malignant ependymoma; median
age at tumour diagnosis, 32 years). In three large NF2 patient
series that were included in this study, 47 of 599 patients (7.8%)
received radiosurgery (DGR Evans et al, unpublished data). By
extrapolation, about 106 of the 1348 patients in this study would
have received radiosurgery, suggesting that malignant transforma-
tion in five of 106 patients was radiation-associated (4717 per 105;
95% CI 681–8753 per 105).
Radiosurgery is typically used for NF2 patients with aggressive
tumours, or who refuse surgery, or who are poor surgical risks or
elderly. The results of this study should not be used to interdict
radiosurgery for these patients; in addition, the results of this study
reflect past exposures and lower doses of ionizing radiation are
used in current radiosurgery protocols. However, observation
without surgery, decompression without tumour removal, and
surgical excision are the preferred therapies for other NF2 patients,
particularly those who are young.
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